Skip to main content

Table 2 Analyses of the associations of sCD73 activity and overall survival

From: Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

  Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Gender (M vs. F) 2.08 (0.80–5.38) P = 0.13 n.s.
Age, years (≥ 62 vs. < 62) 1.09 (0.45–2.65) P = 0.85 n.s.
BRAF status (mut vs. wt) 0.53 (0.19–1.48) P = 0.22 n.s.
LDH, IU/L (≥ 480 vs. < 480) 2.72 (1.07–6.88) P = 0.03 n.s.
Line of treatment (> 2 vs. 2) 2.38 (0.96–5.94) P = 0.06 n.s.
Brain METS (yes vs. no) 1.04 (0.35–3.12) P = 0.94 n.s.
Basal sCD73 activity (≥ 27.8 vs. < 27.8) 6.27 (2.17–18.11) P = 0.001 6.27 (2.17–18.11) P = 0.001
  1. HR hazard ratio, CI confidence interval, n.s. not significant, M male, F female, MUT mutant, WT wild-type, LDH lactate dehydrogenase, IU/L International Units per Liter, METS metastasis, sCD73 soluble CD73
  2. P values are from Cox proportional hazard Regression models